This HTML5 document contains 49 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n15http://localhost/temp/predkladatel/
n16http://linked.opendata.cz/resource/domain/vavai/projekt/
n14http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n19http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n17http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F60162694%3AG44__%2F13%3A43874788%21RIV14-MZ0-G44_____/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n6http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n20http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F60162694%3AG44__%2F13%3A43874788%21RIV14-MZ0-G44_____
rdf:type
skos:Concept n19:Vysledek
rdfs:seeAlso
http://www.sciencedirect.com/science/article/pii/S0378427413001689?via=ihub
dcterms:description
Pigs were administered intramuscularly molar equivalents of HI-6 salts (HI-6 dichloride 10.71 mg/kg and HI-6 DMS 13.59 mg/kg) either with or without hyaluronidase (60 U/kg). Hyaluronidase is supposed to increase tissue permeability and diminishes discomfort caused by the intramuscular injection. Doses of HI-6 salts corresponded with standard HI-6 dichloride dose in one autoinjector (500 mg) and were recalculated for 1 kg of body weight. According to the results, both HI-6 salts applied in combination with hyaluronidase had increased tissue absorption and improved pharmacokinetic profile. The Cmax was significantly higher in case of HI-6 DMS plus hyaluronidase (29.6 +- 2.98 g/ml) administration increase compared to HI-6 DMS (23.8 +- 3.04 g/ml) and HI-6 dichloride (19.0 +- 0.93 g/ml); both without hyaluronidase. Bioavailability calculated as AUCtotal (HI-6 DMS with hyaluronidase, 4119 +- 647 min g/ml) was also significantly higher compared to HI-6 DMS (2259 +- 329 min g/ml) and HI-6 dichloride (1969 +- 254 min g/ml); both without hyaluronidase. The results suggest that administration of HI-6 salt with higher solubility is the first step in the improvement of application strategy, but use some substances with spreading effect (hyaluronidase) may also leads to better absorption and better bioavailability. Improved bioavailability could to go hand in hand with increased effectiveness of therapy without the need of multiple autoinjector applications. Pigs were administered intramuscularly molar equivalents of HI-6 salts (HI-6 dichloride 10.71 mg/kg and HI-6 DMS 13.59 mg/kg) either with or without hyaluronidase (60 U/kg). Hyaluronidase is supposed to increase tissue permeability and diminishes discomfort caused by the intramuscular injection. Doses of HI-6 salts corresponded with standard HI-6 dichloride dose in one autoinjector (500 mg) and were recalculated for 1 kg of body weight. According to the results, both HI-6 salts applied in combination with hyaluronidase had increased tissue absorption and improved pharmacokinetic profile. The Cmax was significantly higher in case of HI-6 DMS plus hyaluronidase (29.6 +- 2.98 g/ml) administration increase compared to HI-6 DMS (23.8 +- 3.04 g/ml) and HI-6 dichloride (19.0 +- 0.93 g/ml); both without hyaluronidase. Bioavailability calculated as AUCtotal (HI-6 DMS with hyaluronidase, 4119 +- 647 min g/ml) was also significantly higher compared to HI-6 DMS (2259 +- 329 min g/ml) and HI-6 dichloride (1969 +- 254 min g/ml); both without hyaluronidase. The results suggest that administration of HI-6 salt with higher solubility is the first step in the improvement of application strategy, but use some substances with spreading effect (hyaluronidase) may also leads to better absorption and better bioavailability. Improved bioavailability could to go hand in hand with increased effectiveness of therapy without the need of multiple autoinjector applications.
dcterms:title
Hyaluronidase: Its effects on HI-6 dichloride and dimethanesulphonate pharmacokinetic profile in pigs Hyaluronidase: Its effects on HI-6 dichloride and dimethanesulphonate pharmacokinetic profile in pigs
skos:prefLabel
Hyaluronidase: Its effects on HI-6 dichloride and dimethanesulphonate pharmacokinetic profile in pigs Hyaluronidase: Its effects on HI-6 dichloride and dimethanesulphonate pharmacokinetic profile in pigs
skos:notation
RIV/60162694:G44__/13:43874788!RIV14-MZ0-G44_____
n3:aktivita
n4:I n4:P
n3:aktivity
I, P(NT12062)
n3:cisloPeriodika
2
n3:dodaniDat
n20:2014
n3:domaciTvurceVysledku
n14:6306888 n14:8765189
n3:druhVysledku
n7:J
n3:duvernostUdaju
n18:S
n3:entitaPredkladatele
n11:predkladatel
n3:idSjednocenehoVysledku
78374
n3:idVysledku
RIV/60162694:G44__/13:43874788
n3:jazykVysledku
n6:eng
n3:klicovaSlova
pigs; oximes; nerve agents; pharmacokinetics; hyaluronidase; HI-6 salts
n3:klicoveSlovo
n12:nerve%20agents n12:oximes n12:pharmacokinetics n12:HI-6%20salts n12:hyaluronidase n12:pigs
n3:kodStatuVydavatele
IE - Irsko
n3:kontrolniKodProRIV
[A99E3DEA2B20]
n3:nazevZdroje
Toxicology Letters
n3:obor
n10:FR
n3:pocetDomacichTvurcuVysledku
2
n3:pocetTvurcuVysledku
5
n3:projekt
n16:NT12062
n3:rokUplatneniVysledku
n20:2013
n3:svazekPeriodika
220
n3:tvurceVysledku
Kuča, Kamil Jun, Daniel Pavlík, Michal Chladek, Jaroslav Žďárová Karasová, Jana
n3:wos
000320595100009
s:issn
0378-4274
s:numberOfPages
5
n17:doi
10.1016/j.toxlet.2013.04.013
n15:organizacniJednotka
G44